The Derivation of Human Embryonic Stem Cell Lines From PGD Embryos

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2025 to Dec 2030v34
  2. Study completion date: Dec 2025 to Dec 2030v33
  3. 4 versions Re-verified since Aug 11, 2021, no change to tracked fieldsv29-v32
  4. Start date: Apr 2004 to Apr 6, 2004
    • Site contact updated
    v28
  5. 2 versions Re-verified since Feb 10, 2020, no change to tracked fieldsv26-v27
Show 24 earlier versionsHide 24 earlier versions
  1. Enrollment target: 30 to 70v25
  2. Primary and study completion dates: Dec 2020 to Dec 2025v24
  3. Re-verified, no change to tracked fieldsv23
  4. Primary and study completion dates: Dec 2018 to Dec 2020v22
  5. 2 versions Re-verified since Sep 1, 2015, no change to tracked fieldsv20-v21
  6. Primary and study completion dates: Dec 2015 to Dec 2018v19
  7. Primary and study completion dates: Dec 2014 to Dec 2015v18
  8. Re-verified, no change to tracked fieldsv17
  9. Primary completion date: Dec 2013 to Dec 2014v16
  10. Primary completion date: Jul 2012 to Dec 2013
    • Study completion date: Oct 2013 to Dec 2014
    v15
  11. 3 versions Re-verified since Nov 1, 2011, no change to tracked fieldsv12-v14
  12. Primary completion date: Jul 2012
    • Study completion date: Oct 2012 to Oct 2013
    v11
  13. Study completion date: Oct 2011 to Oct 2012v10
  14. Study completion date: Oct 2010 to Oct 2011v9
  15. Re-verified, no change to tracked fieldsv8
  16. Study completion date: Oct 2009 to Oct 2010v7
  17. 3 versions Re-verified since May 6, 2008, no change to tracked fieldsv4-v6
  18. Enrollment target: 10 to 30
    • Study completion date: Oct 2008 to Oct 2009
    v3
  19. Study completion date: Oct 2006 to Oct 2008v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Human embryonic stem cells (hESCs) are isolated from the early human embryo and have the capability to proliferate indefinitely in culture and to develop into nearly every cell of the human body. hESC are important for studying developmental biology and for cell replacement therapies for the treatment of degenerative human diseases. An additional use for embryonic stem cells would be for the in vitro study of diseases. hESC lines derived from embryos diagnosed as abnormal by PGD testing would afford such models for study. Because embryos tested by PGD and found to be abnormal would only under rare circumstances be transferred to the uterus of a woman (and in most cases would be discarded), the derivation of new hESC lines from these embryos would provide a viable less ethically-objectionable source of cells with which to study the mechanisms of differentiation and developmental biology.
Trial Details
NCT Number NCT00353210
Lead Sponsor Hadassah Medical Organization
Conditions
(from sponsor)		 Infertility
Related terms Infertility
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov